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Abstract
The primary intent of a chemical probe is to establish the relationship between a molecular target, 
usually a protein whose function is modulated by the probe, and the biological consequences of 
that modulation. In order to fulfill this purpose, a chemical probe must be profiled for selectivity, 
mechanism of action, and cellular activity, as the cell is the minimal system in which ‘biology’ can 
be explored. This review provides a brief overview of progress toward chemical probes for methyl 
lysine reader domains with a focus on recent progress targeting chromodomains.
Introduction
Advances in understanding the regulation of chromatin accessibility via post-translational 
modifications (PTMs) of histones have rejuvenated drug discovery directed toward 
modulation of transcription as the opportunities for pharmacological intervention are 
significantly better than direct perturbation of transcription factors [1–3]. Chemical biology 
is poised to play a central role in advancing scientific knowledge and assessing therapeutic 
opportunities in chromatin regulation. Specifically, cell penetrant, high-quality chemical 
probes that influence chromatin state are of great significance [4,5]. The advantages of a 
small molecule driven approach to modulating chromatin biology are numerous: temporal 
resolution; mechanistic flexibility (targeting a specific activity of a protein as opposed to 
ablating them all via DNA editing and RNA-interference techniques)[6]; ease of delivery; 
and most significantly, a small molecule tool has the potential to provide an immediate 
transition to a drug discovery effort, possibly cutting years off the time between target 
validation and therapeutic intervention [7,8].
While the enzymes that perform PTMs on histones are an important and precedented class 
of druggable targets [1,9], the biological consequences of many PTMs result from their 
recruitment of regulatory machinery via protein-protein interactions (PPI) directly facilitated 
by the PTM [10]. The binding domains involved in PTM recognition on chromatin are 
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referred to as “readers”. We and others have been focused on exploration of the chemical 
biology of readers of methyl-lysine (Kme) as this PTM plays a central role in chromatin 
regulation and more than 200 Kme reader domains within several protein families occur 
within the human proteome, making this a large and relatively unexplored target-class for 
probe discovery [11–21].
Probe Validation
Characterization of selectivity and cellular target engagement are both essential and 
challenging aspects of probe validation [7,16]. In the case of the enzymes that regulate 
chromatin state, a knockdown of the target by siRNA, shRNA or gene editing directly 
perturbs a PTM that can be readily monitored at either a global level or at a specific gene 
locus [1,9]. For Kme readers genetic manipulations tend to result in biochemical or 
phenotypic outcomes that are less easily attributed to specific biochemical changes at the 
level of chromatin. Additionally, since most Kme readers occur in the context of multi-
domain and hence multi-functional proteins, there is no a priori basis to expect that 
pharmacologic antagonism of the Kme reader function will be equivalent to the removal of 
the whole protein in which it is embedded.[6] For this reason, initial assessments of 
chromatin reader antagonism have frequently relied upon the effect of the probe on the 
localization or mobility of a tagged version of its reader target expressed in a cell of interest. 
This approach has been applied to bromodomains [22,23] and Kme readers in our own work 
[19]. While changes in target localization gives a readout that is both proximal to chromatin 
and logically attributable to the likely mechanism of action of the ligand, this 
phenomenology is difficult to relate to any specific biological function of the endogenous 
reader and does not directly establish a molecular pathway connection to phenotypic effects 
[15]. New technologies to assess cellular target engagement could have a significant impact 
on validation of Kme reader probes [24].
Selectivity assessment is perhaps the most important aspect of chemical probe 
characterization, and unfortunately, one that is often lacking in the literature [4,7,25]. While 
single-target specificity is not an absolute requirement, sufficient profiling data to 
confidently attribute in vivo effects to the in vitro profile of a probe are essential. We have 
attempted to address this for Kme readers (in collaboration with the Bedford lab at MD 
Anderson) by evaluating the binding of biotinylated versions of Kme reader probes to a 
nitro-cellulose membrane upon which hundreds of potential chromatin-associated effector 
domains have been spotted [26]. Binding is then observed with a streptavidin-dye conjugate 
and positive results are followed up via quantitative measurements in solution by isothermal 
titration calorimetry (ITC) [13,18]. In addition to assessing selectivity versus Kme reader 
proteins, probes must be profiled versus the enzyme families that modify lysine (PKMTs, 
lysine demethylases), as activity here would be likely to confound interpretation of both 
chromatin biochemical readouts and phenotypic outcomes. There is also a chemical logic for 
screening against these targets since Kme reader probes may mimic the substrates of these 
enzymes. Profiling versus general pharmacology panels is also performed in order to create 
a more complete assessment of potential off-target activities. While this data cannot rule out 
contributions from unexamined or unknown protein off-targets to a probe’s activity, it does 
support the case for specificity when cellular target-engagement has also been proven.[7] 
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Additionally, in the absence of comprehensive profiling data against all possible cellular 
targets, the use of a close structural analogue as an inactive control compound that lacks 
biochemical target activity is critical in order to establish a correlation between on-target in 
vitro activity and cellular effects [25].
Chemical Strategies
Kme binding sites are generally made up of an aromatic cage involving 3 to 4 aromatic 
amino acids, and often an acidic residue to hydrogen bond to the Kme cation in the case of 
mono- and dimethyllysine (Kme1,2) recognition, or simply to balance the charge in the case 
of Kme3 [27,28]. The Patel lab introduced a useful division of Kme readers into “cavity 
insertion” versus “surface groove” binders [29], and subsequent work toward chemical 
probes has been informed by this ontology and confirmed its relevance to ligand design. 
Table 1 illustrates chemical strategies and principles applied thus far to the discovery of Kme 
reader antagonists.
Our initial work focused on ligands for the MBT domains which utilize a cavity insertion 
recognition mode and led to the successful design of the first chemical probe for Kme 
readers, UNC1215 [19]. However, the relatively high affinity of UNC1215 for L3MBTL3 
(Kd = 120 nM) depends upon a unique 2:2 dimer-binding mode that may not be accessible 
or relevant to other Kme reader targets. Based on our current experience, L3MBTL3 is the 
only MBT domain that elicits this recognition mode [30], although we continue to work 
toward Kme reader ligand engagement via dimerization, particularly in cases where this 
binding mechanism may be relevant in vivo, such as 53BP1 [14]. While we and others have 
reported weak Kme ligands discovered by high throughput screening (HTS) of diversity 
libraries [31–35], no hits from HTS have so far been optimized to potent chemical probes 
and our own experience suggests that many HTS hits are false positives that fail to confirm 
in biophysical assays. Kme cavity insertion binders have been largely targeted via traditional 
small molecule strategies (select inhibitors shown in Table 2) and this work has been 
summarized previously [15,36], while more recent progress toward Kme reader probes has 
resulted from ligand discovery efforts towards surface groove binding Kme readers and will 
be reviewed herein.
Peptidomimetic Chromodomain Inhibitors
Cavity insertion binding events between Kme readers and their cognate substrates are 
predominantly driven by localized interactions between the methyl-ammonium and a deep 
protein cleft, making them candidates for intervention with drug-like small molecules, 
whereas surface groove interactions cover a much larger area and rely on contacts with a 
number of adjacent residues in addition to Kme [29]. Consequently, in recent efforts 
targeting chromodomains, which are characterized by an induced fit, surface groove 
interaction with methylated histone substrates, we and others have employed peptide 
mimetic discovery strategies and scaffolds for the successful development of chromodomain 
inhibitors [17,18,37]. These efforts have resulted in inhibitors of the polycomb (Pc) 
chromodomains, well known for their participation in Polycomb repressive complex 1 
(PRC1) [38]. PRC1 is one of the major chromatin regulatory complexes involved in 
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repression of gene transcription, and as such, plays a central role in differentiation and 
development [39,40]. The CBX chromodomains facilitate PRC1-mediated transcriptional 
repression by targeting the complex to the H3K27me3 mark. Consequently, PRC1 
chromodomain chemical probes could be employed to explore the therapeutic potential of 
CBX chromodomains, investigate pharmacologic synergy with inhibitors of the H3K27me3 
methyltransferase, EZH2 [41], and understand the precise roles of CBX target genes in 
different cancer types.
There are five human proteins that belong to the polycomb chromodomain family: CBX2, 
-4, -6, -7, and -8; all of which share a high level of sequence identity within their 
chromodomains, suggesting that development of selective inhibitors could be a challenge. 
Ligand design must also take into account the shallow aromatic cage that binds Kme3 and 
the continuous β-sheet-like interaction that includes a sequence of hydrogen bonds with the 
histone backbone; therefore development of peptidomimetic ligands has been pursued, 
despite the anticipated difficulties in cell permeability.
Hof and co-workers reported the first inhibitors of a chromodomain, CBX7, derived from a 
five-residue peptide sequence (FALKme3S) from the protein SETDB1, which was reported 
to have slightly higher in vitro affinity for CBX7 than the H3K27me3 sequence itself 
[17,42]. They performed a systematic study in which each amino acid of the parent peptide 
was substituted with both natural and unnatural residues, and the affinity of these and 
subsequently derived ligands for CBX7 was determined by fluorescence polarization and 
ITC. Iterative ligand design was further guided by X-ray crystallography and 2D NMR 
structural studies of ligands bound to CBX7. Upon evaluation of the tolerance of each site to 
modification, select compounds bearing multiple well-tolerated substitutions were prepared. 
This ultimately led to compound 64 (Figure 1a), which binds CBX7 with a Kd of 
approximately 200 nM and bears a number of modifications relative to the FALKme3S 
sequence. The most significant potency enhancement results from a benzoic amide at the N-
terminus. The affinity of compound 64 for three other chromodomains was determined; 
resulting in 10-fold selectivity over CBX8, equal potency for CBX4, and no measurable 
affinity for the HP1 family chromodomain, CBX1.
More recently, the Hof group has elegantly demonstrated the ability of peptidomimetics to 
achieve selectivity within the family of polycomb CBX chromodomains. Structural 
knowledge of the features broadly required for CBX binding led to modification of the 
residue two amino acids from the Kme3 site (−2 position) which resulted in enhanced CBX 
selectivity [37]. Fluorescently labeled ligands were profiled against CBX2, -4, -6, -7, -8, and 
the HP1 paralog CBX1 via direct fluorescent polarization (FP) titrations. Inclusion of an 
isopropyl group in compound 5 at the (−2) position resulted in 90-, 20-, 18-, 6-, and 7-fold 
selectivity for CBX6 over CBX1, -2, -4, -7, and -8, respectively, accompanied by only a 3-
fold loss in potency for CBX6 (Kd = 0.9 μM) relative to the analogous alanine containing 
compound (Figure 1a). This reveals that subtle modifications to this ligand scaffold are able 
to greatly diminish CBX7 binding and clearly demonstrates that occupying binding sites 
other than the Kme3-binding aromatic cage can modulate potency and selectivity.
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Concurrent to the efforts of the Hof group, we initiated a program to discover high-quality 
chemical probes of the polycomb CBX chromodomains based on their known disease 
relevance, guided largely by molecular dynamics simulations, cocrystallization studies, and 
structure-activity relationships. This led to the design and characterization of UNC3866 
(Figure 1), which binds the chromodomains of CBX4 and CBX7 most potently (Kd 
~100nM), and is 6- to 18-fold selective as compared to the other polycomb CBXs [18]. 
Knowledge of the activity profile of a molecule is essential in order to associate its cellular 
effects with the modulation of a specific molecular target(s); therefore, UNC3866 was 
evaluated against >250 other protein targets including Kme readers, bromodomains 
(acetyllysine reader proteins), protein methyltransferases and demethylases, and GPCRs (G 
protein coupled receptors), among others (Figure 2). This revealed that in addition to the 
known polycomb targets, UNC3866 binds three members of the CDY family of 
chromodomains (CDY1, CDYL1b, and CDYL2). Importantly, UNC3866 was also shown to 
engage the intact PRC1 complex, antagonize PRC1 chromodomains in cells, exhibit a high 
level of stability in cells, and inhibit PC3 cell proliferation (a known CBX7 phenotype), 
supporting further investigation of PRC1 chromodomain antagonists as oncology 
therapeutics. The replacement of the quaternary amine of the native peptide ligand with an 
unnatural tertiary amine mimetic was a key achievement in the development of a cellularly 
active ligand, despite its relatively low permeability, and signifies that a quaternary amine is 
not essential for inhibition of Kme3 reader proteins. The design and concomitant use of an 
inactive negative control compound, differing from UNC3866 by addition of a single methyl 
group, further supported the characterization of UNC3866 as the first high-quality chemical 
probe for a chromodomain. Taken together, our progress toward cellularly active, peptidic 
chromodomain antagonists and the Hof’s group demonstration of selectivity tuning within 
the PRC1 chromodomains bodes well for further breakthroughs in this area.
Conclusions
The pursuit of well validated chemical probes for Kme reader proteins represents an 
emerging area of chemical biology that will create new understanding of chromatin 
regulation and prove useful in validation of Kme readers implicated in disease. As this 
target-class is well represented in databases of proteins genetically altered in cancer and 
neurological diseases [43], the opportunity for translational impact is promising. While 
peptidic probes seem most likely to deliver high-affinity and selectivity for groove-binding 
Kme readers, such as chromodomains, progress toward more drug-like compounds for these 
domains could be spurred on by target validation studies with peptide-like chemical probes. 
[44,45]
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Highlights
• Methyl lysine reader domains are a major class of chromatin regulatory 
modules that are being explored for therapeutic relevance.
• Chemical probes are molecules that are suitable for target validation 
studies in cells based on their potency, demonstrated target 
engagement, and selectivity.
• Recent progress toward methyl lysine reader domain chemical probes 
has resulted in potent, cellularly active and selective ligands for the 
chromodomains of the polycomb repressive complex 1.
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Figure 1. Peptidomimetic chromodomain ligands
a) Chemical structures of peptidic chromodomain inhibitors. b) Co-crystal structure of 
chemical probe UNC3866 bound to CBX7 (pdb 5EPJ). The protein surface is shown in light 
blue and UNC3866 in yellow. Hydrogen bonds between the protein and UNC3866 are 
shown by a black dotted line.
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Figure 2. Selectivity profile of UNC3866
UNC3866 antagonizes the Kme reading function of the Polycomb CBX and the CDY 
families of chromodomains and is highly selective over >250 other protein targets evaluated. 
The affinity of UNC3866 for its chromodomain targets was determined by ITC.
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Table 1
Chemical strategies and principles applied to the discovery of antagonists for cavity insertion methyllysine 
binders and surface groove methyllysine binders.
Cavity Insertion Binders Surface Groove Binders
Hit Discovery & 
Screening 
Strategies
Screen focused small molecule or fragment libraries
Employ target class cross screening
Utilize structure-based design for hit optimization
Apply structure-based design
Screen peptide or peptoid libraries
Design Principles Exploit cation-π and H-bonding interactions in aromatic 
cage
Utilize conformational constrained alkyl amines
Use available Kme peptide SAR
Target binding sites adjacent to aromatic cage
Introduce unnatural amino acids, Kme mimics, and non-
peptidic features
Major Challenge Fragment-like size may result in low affinity Low cell permeability may decrease overall utility
Example L3MBTL1 + H4K20me2 (pdb 2PQW) CBX7 + H3K27me3 (pdb 4X3K)
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